Abstract 18120: High Density Lipoprotein Particles Predict All-cause and Cardiovascular Mortality
Introduction: The concentration and size of HDL particles are considered to be related to their atheroprotective properties. This study in patients at increased cardiovascular risk was performed to evaluate the associations of HDL particle characteristics with all-cause and cardiovascular mortality.
Methods and Results: HDL particle concentrations for all sizes and for size categories (7-8.5 nm, 8.5-10 nm, 10-13 nm, and 13-16 nm) were measured in 2,290 participants of the LURIC study (1,575 males, 715 females) by nuclear magnetic resonance spectroscopy. Mean (standard deviation) age was 62.9 (10.4) years, body mass index was 27.6 (4.1) kg/m2, HDL cholesterol was 39 (11) mg/dl, and HDL particle concentration for all sizes was 25.1 (6.0) μmol/l. During a median (interquartile range) follow-up of 10.0 (6.1-10.6) years, 662 participants died from any cause and 434 from cardiovascular diseases. In multivariable analyses including adjustment for HDL cholesterol tertiles of HDL particle concentrations for all sizes were inversely related to all-cause (3rd vs. 1st tertile: HR [95%CI] = 0.69 [0.55-0.87], P=0.001) and cardiovascular mortality (HR [95%CI] = 0.67 [0.50-0.89], P=0.007). These associations were primarily mediated by the inverse relationship between the smallest HDL particles (7-8.5 nm) and endpoints (P≤0.005). The associations of larger HDL particles (8.5-10 nm, 10-13 nm, and 13-16 nm) with endpoints were less pronounced and did not reach statistical significance in multivariable analyses (all P>0.1).
Conclusions: In participants of the LURIC study high concentrations of HDL particles predict decreased cardiovascular risk. This association is mainly driven by small HDL particles.
Author Disclosures: G. Silbernagel: Consultant/Advisory Board; Modest; AMGEN. Research Grant; Significant; Unilever. P. Pagel: Employment; Significant; Numares. V. Pfahlert: Employment; Significant; Numares. B. Genser: Research Grant; Significant; Numares, Danone. H. Scharnagl: None. M.E. Kleber: None. G. Delgado: None. A. Ritsch: None. T.B. Grammer: None. I. Baumgartner: None. W. Koenig: None. W. März: Employment; Significant; Synlab. Research Grant; Significant; AMGEN, Danone, Numares, Unilever. Honoraria; Significant; Roche. Ownership Interest; Significant; Synlab.
- © 2015 by American Heart Association, Inc.